For all subgroups, including drug target (PD‐1 or PD‐L1), therapy type (monotherapy or combination therapy), drug type and different lines of treatment subgroups, the PD‐L1‐positive HCC patients had a higher ORR than the PD‐L1‐negative HCC patients; statistical significances were observed in the PD‐1 target subgroup, monotherapy subgroup, nivolumab subgroup, and first‐line treatment subgroup. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.